All In Biotech

Drug Trial Radar · NCT04339140

Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer

A Phase 2 Study of Zafirlukast for the Treatment of Tumor-marker Only Relapsed Ovarian Cancer

Last checked: Nov 20, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

5

Actual

Start

Jun 24, 2020

Primary completion

Dec 31, 2023

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Beth Israel Deaconess Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institutes of Health (NIH); National Cancer Institute (NCI); Dana-Farber Cancer Institute
First posted
Apr 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is evaluating the effectiveness of Zafirlukast to prevent tumor activity in participants with tumor marker-only relapsed ovarian cancer. * The name of the study drug involved in this study is: * Zafirlukast

Conditions

  • Ovarian Cancer

Interventions

  • ZafirlukastDrug

    Oral tablets, 2x daily for 28 day cycle up to 1 year

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CA-125 Response RateTime frame: 84 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.